These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 10476928)

  • 1. Oral use of interferon.
    Cummins JM; Beilharz MW; Krakowka S
    J Interferon Cytokine Res; 1999 Aug; 19(8):853-7. PubMed ID: 10476928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of low-dose oral use of type I interferon in cytomegalovirus infections in vivo.
    Bosio E; Beilharz MW; Watson MW; Lawson CM
    J Interferon Cytokine Res; 1999 Aug; 19(8):869-76. PubMed ID: 10476931
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose oral use of interferon inhibits virally induced myocarditis.
    Lawson CM; Beilharz MW
    J Interferon Cytokine Res; 1999 Aug; 19(8):863-7. PubMed ID: 10476930
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of orally/sublingually, intranasally, and intraperitoneally administered recombinant murine interferon in the treatment of murine encephalomyocarditis virus.
    Sonnenfeld G; Tovey M; Schellekens H; Kinney KS; Belay T; Morton DS; Austin CE; Reitman M; Fong TA; Vaughan HS
    J Interferon Cytokine Res; 2001 Jul; 21(7):539-45. PubMed ID: 11506749
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of oromucosally administered interferon-alpha in the prevention and treatment of animal diseases.
    Dec M; Puchalski A
    Pol J Vet Sci; 2008; 11(2):175-86. PubMed ID: 18683548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Natural human interferon-alpha administered orally as a treatment of bovine respiratory disease complex.
    Cummins JM; Guthrie D; Hutcheson DP; Krakowka S; Rosenquist BD
    J Interferon Cytokine Res; 1999 Aug; 19(8):907-10. PubMed ID: 10476937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oromucosal interferon therapy: marked antiviral and antitumor activity.
    Tovey MG; Maury C
    J Interferon Cytokine Res; 1999 Feb; 19(2):145-55. PubMed ID: 10090400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action.
    Tompkins WA
    J Interferon Cytokine Res; 1999 Aug; 19(8):817-28. PubMed ID: 10476925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Future perspectives: towards interferon-free regimens for HCV.
    Gane E
    Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic hepatitis C virus infection in renal transplant: treatment and outcome.
    Sharma RK; Bansal SB; Gupta A; Gulati S; Kumar A; Prasad N
    Clin Transplant; 2006; 20(6):677-83. PubMed ID: 17100715
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mucosal cytokine therapy: marked antiviral and antitumor activity.
    Tovey MG; Meritet JF; Guymarho J; Maury C
    J Interferon Cytokine Res; 1999 Aug; 19(8):911-21. PubMed ID: 10476938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Consensus interferon and ribavirin for patients with chronic hepatitis C and failure of previous interferon-alpha therapy.
    Böcher WO; Schuchmann M; Link R; Hillenbrand H; Rahman F; Sprinzl M; Mudter J; Löhr HF; Galle PR
    Liver Int; 2006 Apr; 26(3):319-25. PubMed ID: 16584394
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose oral administration of interferon-alpha for the treatment of immune-mediated keratoconjunctivitis sicca in dogs.
    Gilger BC; Rose PD; Davidson MG; Roberts SM; Miller T
    J Interferon Cytokine Res; 1999 Aug; 19(8):901-5. PubMed ID: 10476936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SNPs in the promoter region of the osteopontin gene as a marker predicting the efficacy of interferon-based therapies in patients with chronic hepatitis C.
    Naito M; Matsui A; Inao M; Nagoshi S; Nagano M; Ito N; Egashira T; Hashimoto M; Mishiro S; Mochida S; Fujiwara K
    J Gastroenterol; 2005 Apr; 40(4):381-8. PubMed ID: 15868370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential treatment with lamivudine and interferon monotherapies in patients with chronic hepatitis B not responding to interferon alone: results of a pilot study.
    Serfaty L; Thabut D; Zoulim F; Andreani T; Chazouillères O; Carbonell N; Loria A; Poupon R
    Hepatology; 2001 Sep; 34(3):573-7. PubMed ID: 11526544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of primary Sjögren's syndrome with low-dose natural human interferon-alpha administered by the oral mucosal route: a phase II clinical trial. IFN Protocol Study Group.
    Ship JA; Fox PC; Michalek JE; Cummins MJ; Richards AB
    J Interferon Cytokine Res; 1999 Aug; 19(8):943-51. PubMed ID: 10476942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon therapy.
    Williams CN
    Can J Gastroenterol; 1997 Oct; 11(7):563-4. PubMed ID: 9395755
    [No Abstract]   [Full Text] [Related]  

  • 18. Outcome of treatment with pegylated interferon and ribavirin in heart transplant recipients with chronic hepatitis C.
    Durante-Mangoni E; Ragone E; Pinto D; Iossa D; Covino FE; Maiello C; Utili R
    Transplant Proc; 2011; 43(1):299-303. PubMed ID: 21335209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C.
    McHutchison JG; Shiffman ML; Cheung RC; Gordon SC; Wright TL; Pottage JC; McNair L; Ette E; Moseley S; Alam J
    Antivir Ther; 2005; 10(5):635-43. PubMed ID: 16152757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of acute hepatitis C].
    García Compeán D
    Rev Gastroenterol Mex; 2002 Oct; 67 Suppl 2():S61-6. PubMed ID: 12712857
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.